Atea Pharmaceuticals is creating new nucleotide antivirals, including one the company is jointly developing with Roche to fight COVID-19.
AltruBio’s new approach — regulating a checkpoint to mediate T cells in immune diseases — can surprise people more familiar with checkpoint-blocking cancer treatments now on the market.
AMO Pharma is applying “de-risked” compounds as potential medicines for rare diseases in brain development.
NervGen Pharma is going beyond preclinicals to human trials for a drug that could repair and regrow neurons.
Our company to watch this month is IM Therapeutics, which focuses on developing small molecule therapies for Type 1 diabetes, celiac disease, and other autoimmune conditions.
Our company to watch this month, Lyra Therapeutics, is focused on controlling chronic ENT conditions with precise drug elution and long action.
Carisma Therapeutics is a private company developing CAR-M (chimeric antigen receptor macrophage) as an alternative to CAR-T (CAR-T cell) and potential treatment for solid tumors rather than just liquid cancers.
PhaseBio is a small, public company aiming to enter a large-market therapeutic area: cardiovascular.
Companies To Watch: Akero Therapeutics - Test-proofing a new metabolism drug to beat the liver disease, NASH
Artax Biopharma is challenging the immunosuppressive paradigm with a novel drug for autoimmune diseases.
Get the latest articles from Life Science Leader delivered to your inbox.